Targeting replication stress in cancer therapy
AABA da Costa, D Chowdhury, GI Shapiro… - Nature reviews Drug …, 2023 - nature.com
Replication stress is a major cause of genomic instability and a crucial vulnerability of
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …
Doxorubicin—an agent with multiple mechanisms of anticancer activity
Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens
currently in clinical use. However, the precise mechanisms of DOX's action are not fully …
currently in clinical use. However, the precise mechanisms of DOX's action are not fully …
Programmed death ligand 1 signals in cancer cells
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
Regulation of PD-L1 expression in the tumor microenvironment
M Yi, M Niu, L Xu, S Luo, K Wu - Journal of hematology & oncology, 2021 - Springer
Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …
State-of-the-art strategies for targeting the DNA damage response in cancer
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …
damage response (DDR) and/or increased replication stress. These alterations promote the …
Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer
Despite recent advances in the use of immunotherapy, only a minority of patients with small
cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB). Here, we show that …
cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB). Here, we show that …
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
A Marra, D Trapani, G Viale, C Criscitiello… - NPJ breast …, 2020 - nature.com
Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
[HTML][HTML] Mechanisms controlling PD-L1 expression in cancer
The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene)
receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; …
receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; …
ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer
Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-
associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor …
associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor …